Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early Access Program of Rintatolimod in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Pancreatic Cancer

Next Previous
Trial Profile

Early Access Program of Rintatolimod in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Pancreatic Cancer

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rintatolimod (Primary) ; 5-fluorouridine; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Chronic fatigue syndrome; Encephalomyelitis; Pancreatic cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors AIM ImmunoTech

    • Most Recent Events

    • 25 Mar 2024 According to an AIM ImmunoTech media release, a new data analysis from a long-term Early Access Program (EAP) studying the company drug Ampligen (rintatolimod) for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) has been published in the Journal Clinical Cancer Research.
    • 04 Oct 2021 According to an AIM ImmunoTech media release, Prof. C.H.J. van Eijck, MD, PhD, and his team at Erasmus MC intend to publish detailed clinical report on the results in a peer-reviewed journal no later than January 2022 and AIM will publicly release the detailed data and analysis at that time.
    • 10 Feb 2021 According to an AIM ImmunoTech media release,the Dutch Health and Youth Care Inspectorate (IGJ) has approved treatment for six pancreatic cancer patients as part of a new, follow-up Early Access Program (EAP) at Erasmus Medical Center in the Netherlands.Subject to further authorization we plan to treat up to 16 pancreatic cancer patients with rintatolimod (Ampligen) under the EAP,
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top